Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Novel Psychoactive Substances Most Commonly Identified in Clinical Specimens from November 2023 to April 2024

SOFT 2024

Society of Forensic Toxicologists

St Louis, MO Oct 27-31, 2024

Poster presentation: Novel Psychoactive Substances Most Commonly Identified in Clinical Specimens from November 2023 to April 2024

Authors: Neifeld JR, Meli TM, Smith MP, Bartock SH

Specialty: Prescription Drug Monitoring, Toxicology

Related content

Test FAQ
Novel Psychoactive Substances (NPS) Panel
Publication
Implementation of the first comprehensive state oral fluid drug testing program for roadside screening and laboratory testing in DUID cases - a five-year review
Publication
Development, validation, and clinical assessment of a liquid chromatography-tandem mass spectrometry serum assay for per- and polyfluoroalkyl substances (PFAS) recommended by the National Academies of Science, Engineering, and Medicine (NASEM)
Audio Podcast
Dangerous Drug Combinations
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.